

Summary statistics - quantitative results
(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E12/20 - Hormones 1

Deadline: 05.05.2020

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability																		
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}			
(121) Total T3					2									2	2	100%						2	1	50%	
— Samples and groups —	[nmol/L]																								
Sample A		5,28	0,38	7,2	2									2	2	100%	CRV	6,4	0,085	20%	5,12	7,68	2	1	50%
Other					2	0								2									2		
							1x 4/1, 1x 4/29										1x 4/1, 1x 4/29								
Sample B		1,65	0,04	2,7	2									2	2	100%	CRV	2,049	0,020	20%	1,63	2,46	2	1	50%
Other					2	0								2									2		
							1x 4/1, 1x 4/29										1x 4/1, 1x 4/29								
(122) Total T4					2									2	2	100%						2	2	100%	
— Samples and groups —	[nmol/L]																								
Sample A		198	1,8	0,91	2									2	2	100%	CRV	201,3	2,3	17%	167	236	2	2	100%
Other					2	0								2									2		
							1x 4/1, 1x 4/29										1x 4/1, 1x 4/29								
Sample B		230	10	4,4	2									2	2	100%	CRV	261,2	2,9	17%	216	306	2	2	100%
Other					2	0								2									2		
							1x 4/1, 1x 4/29										1x 4/1, 1x 4/29								
(123) TSH					29									29	29	100%						0			
— Samples and groups —	[mU/L]																								
Sample A		6,34	0,55	8,6	29									29	29	100%						0			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		5,46	0,04	0,79	5	0	CVPG	5,7	0,052	14%	4,9	6,5		5											
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		6,20	0,28	4,6	7	0	CVPG	6,12	0,061	14%	5,26	6,98		7											
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		6,60	0,26	3,9	12	0	CVPG	6,53	0,024	14%	5,61	7,45		12											
Other					5	0								5											
							1x 3/25, 1x 4/29, 1x 4/149, 2x 4/179																		
Sample B		5,06	0,52	10	29									29	29	100%						0			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		3,98	0,02	0,56	5	0	CVPG	4,1	0,037	14%	3,52	4,68		5											
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		5,00	0,23	4,7	7	0	CVPG	4,86	0,042	14%	4,17	5,55		7											
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		5,44	0,22	4,0	12	0	CVPG	5,44	0,018	14%	4,67	6,21		12											
Other					5	0								5											
							1x 3/25, 1x 4/29, 1x 4/149, 2x 4/179																		
(124) Free T4					28									28	27	96%						0			
— Samples and groups —	[pmol/L]																								
Sample A		41,7	7,6	18	28									28	27	96%						0			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		30,4	0,81	2,7	5	0	CVPG	30,9	0,33	13%	26,8	35		5											
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		42,9	1,8	4,2	7	0	CVPG	42,7	0,58	13%	37,1	48,3		7											
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		47,0	1,2	2,5	12	0	CVPG	47,3	0,24	13%	41,1	53,5		12											

Summary statistics - quantitative results
(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E12/20 - Hormones 1

Deadline: 05.05.2020

Test	[unit]	Comparability					Traceability																	
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
(124) Free T4					28							28	27	96%									0	
Samples and groups	[pmol/L]																							
Sample A		41,7	7,6	18	28							28	27	96%									0	
Other					4	0						4												
Sample B		54,2	13	24	28							28	27	96%									0	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		36,9	2,3	6,3	5	0	CVPG	38,2	0,53	13%	33,2	43,2		5										
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		50,8	1,3	2,5	7	0	CVPG	50,8	0,69	13%	44,1	57,5		7										
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		64,9	2,4	3,7	12	0	CVPG	65	0,38	13%	56,5	73,5		12										
Other					4	0								4										
(125) Free T3					19							19	19	100%									0	
Samples and groups	[pmol/L]																							
Sample A		25,4	4,9	19	19							19	19	100%									0	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		20,8	1,6	7,6	5	0	CVPG	20,2	0,27	15%	17,1	23,3		5										
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		29,3	0,54	1,8	9	0	CVPG	29,5	0,087	15%	25	34		9										
Other					5	0								5										
Sample B		7,12	0,96	14	19							19	19	100%									0	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		6,50	0,30	4,6	5	0	CVPG	6,25	0,083	15%	5,31	7,19		5										
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		7,69	0,28	3,7	9	0	CVPG	7,61	0,030	15%	6,46	8,76		9										
Other					5	0								5										
(200) Ferritin					22							21	16	76%									0	
Samples and groups	[µg/L]																							
Sample A		108	19	18	22							21	21	100%									0	
Other					22	0						21												
Sample B		17,5	4,6	26	22							21	16	76%									0	
Other					22	0						21												
(301) Cortisol					13							13	11	85%									13	
Samples and groups	[nmol/L]																						10	
Sample A		1030	170	17	13							13	11	85%	CRV	1029	11	22%	802	1260		13	10	77%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		1030	79	7,7	5	0	CVPG	1000	27	16%	840	1160		5								5		
Other					8	0								8									8	
Sample B		277	41	15	13							13	12	92%	CRV	305,9	3,7	22%	238	374		13	11	85%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		244	0,89	0,36	5	0	CVPG	247	6,4	16%	207	287		5								5		
Other					8	0								8									8	

Summary statistics - quantitative results
 (Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E12/20 - Hormones 1

Deadline: 05.05.2020

Test	[unit]	Comparability						Traceability															
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(305) Testosterone	[nmol/L]				19							18	17	94%							19	19	100%
--- Samples and groups ---																							
Sample A		4,16	0,31	7,4	19							18	18	100%	CRV	4,615	0,054	30%	3,23	6	19	19	100%
Other					4	0						3									4		
(306) 17-OH-progesterone	[nmol/L]				4							3	3	100%							4	3	75%
--- Samples and groups ---																							
Sample A		14,1	10	73	4							3	3	100%	CRV	7,113	0,071	44%	3,98	10,3	4	3	75%
Other					4	0						3									4		
Sample B		6,74	4,0	59	4							3	3	100%	CRV	3,219	0,032	±2,641	0,579	5,86	4	3	75%
Other					4	0						3									4		
(307) DHEA-S	[µmol/L]				10							10	8	80%							0		
--- Samples and groups ---																							
Sample A		13,0	2,1	16	10							10	9	90%							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		14,7	0,17	1,2	5	0	CVPG	14,1	0,15	21%	11,1	17,1	5										
(60) Roche																							
Other					5	0							5										
Sample B		6,46	0,72	11	10							10	9	90%							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		6,76	0,46	6,8	5	0	CVPG	6,35	0,068	21%	5,01	7,69	5										
(60) Roche																							
Other					5	0							5										

st_kn_np

End of report

Printed: 21.05.2020